Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ATR senses stiff extracellular matrix to promote epithelial-to-mesenchymal transition and immune suppression.

The Journal of clinical investigation·2026
Same author

Tumor infiltrating lymphocytes (TILs) as a predictive marker of pathological complete response (pCR) in a diverse patient population with early triple negative breast cancer (TNBC) treated with neoadjuvant real-world KEYNOTE-522 regimen.

Breast cancer research and treatment·2026
Same author

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.

Breast cancer research and treatment·2026
Same author

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.

Breast cancer research and treatment·2026
Same author

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.

medRxiv : the preprint server for health sciences·2026
Same author

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Apr 12, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.2K

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.

Maeve A Hennessy1, Elizabeth Terman2, Damé Idossa3

  • 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|April 10, 2026
PubMed
Summary

Triple-negative breast cancer (TNBC) treatments are evolving with antibody-drug conjugates (ADCs) and immune checkpoint inhibitors. Further research is needed for novel agents and biomarkers to improve outcomes for this aggressive cancer.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 12, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.2K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Triple-negative breast cancer (TNBC) lacks ER, PR, and HER2 targets, limiting treatment options.
  • Existing therapies like chemotherapy with immune checkpoint inhibitors benefit only a subset of patients.
  • TNBC has poorer outcomes compared to other breast cancer subtypes.

Purpose of the Study:

  • To review current evidence and future challenges in advanced TNBC treatment.
  • To highlight the role of novel therapeutic strategies, including antibody-drug conjugates (ADCs).
  • To emphasize the need for predictive biomarkers and optimized treatment sequencing.

Main Methods:

  • Literature review of current evidence in advanced TNBC.
  • Analysis of the impact of immune checkpoint inhibitors and ADCs.
  • Discussion of molecular heterogeneity and personalized therapeutic strategies.

Main Results:

  • Immune checkpoint inhibitors offer benefits for PD-L1-positive metastatic TNBC.
  • ADCs represent a promising advance, moving into earlier treatment stages.
  • Despite progress, TNBC remains challenging with unfavorable outcomes.

Conclusions:

  • Advanced TNBC requires more effective therapies beyond current options.
  • Optimizing therapeutic sequencing and developing predictive biomarkers are crucial.
  • Novel agents are essential to address the unmet needs in TNBC management.